Beyond RECIST
As a surrogate endpoint to measure response to treatment…
The Choi Criteria in Oncology Clinical Trials
The Choi imaging criteria can provide insight about anti-tumor activity…
Using PCWG3 Classification in Prostate Cancer
The PCWG3 Classification, published in 2016…
Tumor Growth Kinetic Modeling
Heterogeneity is a well-recognized feature of malign…
Using 18FDG-PET and Other PET Agents in Oncology Clinical Trials
Imaging Endpoints has maintained a leadership…
THE RANO CRITERIA AND KEEPING PACE WITH DISCOVERY
Ten years have passed since the publication of the…
Response Assessment in Lymphoma: The Lugano Classification and Beyond
The Lugano Classification published in 2014 and also…
Radiomics: The 13th Hallmark of Cancer – From Black Box to Shade of Lights in Imaging Analysis
Radiomic analysis is a high-throughput method that quantifies…
Optimizing Imaging Response Criteria for Improved Outcomes in Oncology Clinical Trials
How optimizing imaging response criteria streamlines successful trial completion, favors regulatory approval, expedites the time-to-market, and amplifies patient benefits.
